Join us in the Fight Against Niemann-Pick Type C Disease

Ara Parseghian Medical Research Fund

Currently Funded Grants

As of July 1, 2016

Fabien Alpy, Ph.D., Researcher, French National Institute of Health and Medical Research (INSERM) – TITLE: The cholesterol transfer protein STARD3: a new therapeutic target in Niemann Pick C disease.

Gregorio Gil, Ph.D., Professor, Department of Biochemistry and Molecular Biology, Medical College of Virginia, Virginia Commonwealth University – TITLE: Activation of StarD4 corrects the NPC Phenotype.

Paul Helquist, Ph.D., Professor and Associate Chair for Research, Department of Chemistry and Biochemistry, The University of Notre Dame – TITLE: Design and Synthesis of Small Molecule Therapeutic Agents and Biochemical Probes for the Treatment and Study of Niemann-Pick Type C Disease.

Frederick R. Maxfield, Ph.D., Professor and Chair, Department of Biochemistry, Weill Cornell Medical College – TITLE: In Vitro tests of the efficacy of therapies for Niemann-Pick C disease.

Suzanne R. Pfeffer, Ph.D., Professor and Chairman of Biochemistry, Stanford University, School of Medicine – TITLE: NPC1-medicated export of cholesterol from lysosomes.

Kevin T. Vaughan, Ph.D., Associate Professor, Department of Biological Sciences, University of Notre Dame – TITLE: StARD9 as a Genetic Modifier of Niemann Pick Type C Disease.

Jing Zheng, Ph.D., Associate Professor, Department of Communication Sciences and Disorders, Northwestern University – TITLE: Investigate the Effectiveness of Salicylate in Preventing HPβCD-Induced Ototoxicity in the NPC1 Mouse Model.

Return to Research Section